知镜 Cognispect · 医学文献与研究工作台

Thyroid eye disease: Established and emerging therapies.

Samia-Aly E, Penarrocha S, Ramsewak S, Vahdani K, Verity DH, Uddin JM.
Best practice & research. Clinical endocrinology & metabolism · 2026-08-15 · PMID 42629268

文献摘要

Thyroid eye disease is an immune-mediated orbital disorder most commonly associated with Graves' disease. Inflammatory expansion of orbital tissues causes proptosis, exposure symptoms, diplopia, and, in severe cases, dysthyroid optic neuropathy, with significant physical and psychological impact. Maintaining euthyroidism and promoting smoking cessation are central in its management; requiring close coordination between Ophthalmology and Endocrinology teams. Management of thyroid eye disease is guided by disease activity, severity, and phenotype, with the greatest response to immunomodulatory therapy occurring during the active inflammatory phase. Established therapies include glucocorticoids, orbital radiotherapy, steroid sparing agents, whilst newer options such as biologics have expanded the therapeutic landscape. Surgical treatments are important in treating sight threatening disease refractory to medical therapy and in staged rehabilitation once disease inactivity and thyroid stability are achieved. This review outlines established as well as emerging therapies.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。